title: [Blastoschizomyces capitatus fungemia: three case reports and review of the literature].
abstract: Blastoschizomyces capitatus is a rare fungal pathogen that may lead to fatal infections especially in immunosuppressive individuals. In this report, three cases of B.capitatus were presented. The patients were under treatment for acute myeloid leukemia and their blood cultures yielded B.capitatus. The patients clinical conditions deteriorated and they died despite amphotericin B treatment. The isolates were identified by conventional mycological methods and API 20C AUX (Bio-Mérieux, France) system. Antifungal susceptibility test of the strains was performed with Sensititre Yeast One Panel (Trek Diagnostic Systems, USA) and minimum inhibitory concentration (MIC) ranges for amphotericin B, caspofungin, fluconazole, itraconazole, voriconazole, posaconazole, and flucytosine were found as 0.5-1; > 16; 8-16; 0.5; 0.25; 0.5-1 and 0.06-0.25 µg/ml, respectively. Isolated strains were genotyped with RAPD-PCR (Random Amplified Polymorphic DNA-Polymerase Chain Reaction) using Cnd-3, Cnd-4, OPE-03, OPE-18 primers. The strains isolated from the first two cases were found to be genotypically identical, while the strain isolated from the third case was different. Genotypically identical isolates belonged to two patients who were admitted to the hospital with approximately 18 months interval. The other strain with a unique genotype, was isolated from a patient who was admitted to the hospital about two years later than the other two patients. In conclusion, B.capitatus should be considered as an important opportunistic pathogen especially in patients with hematologic malignancies. The data of this study demonstrated that the lowest MIC values for B.capitatus strains were with voriconazole.
authors.affiliation: Adnan Menderes University Medicine and Health Sciences Center Research, Department of Medical Microbiology, Aydın, Turkey. gultekinberna@hotmail.com
authors.forename: Berna
authors.initials: B
authors.lastname: Gültekin
authors.forename: Irfan
authors.initials: I
authors.lastname: Yavaşoğlu
authors.forename: Mete
authors.initials: M
authors.lastname: Eyigör
authors.forename: Gürhan
authors.initials: G
authors.lastname: Kadıköylü
authors.forename: Zahit
authors.initials: Z
authors.lastname: Bolaman
authors.forename: Neriman
authors.initials: N
authors.lastname: Aydın
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000382:microbiology*; D005838:Genotype; D006801:Humans; D016867:Immunocompromised Host; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000628:therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D019105:Random Amplified Polymorphic DNA Technique; D004718:Saccharomycetales / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B